安全可靠的 Molecules of Korolchuk IP-NFT 钱包
通过 Trezor 生态系统,全面自信地掌控您的Molecules of Korolchuk IP-NFT资产。
- 由您的硬件钱包保护
- 搭配兼容的热钱包使用
- 全球超 200 万用户信赖

收发您的 Molecules of Korolchuk IP-NFT 通过 Trezor Suite 应用
收发
支持Molecules of Korolchuk IP-NFT的 Trezor 硬件钱包
让您的 Trezor 同步至钱包应用
支持的Molecules of Korolchuk IP-NFT网络
为什么要用硬件钱包?
离线安全保护,尽在 Trezor
- 您 100% 拥有您的加密货币
- 离线保护私钥,大幅降低在线攻击风险
- 您的数据 100% 匿名
- 您的加密货币不受任何公司控制
在线交易所
- 若交易所出现问题,您将失去加密货币
- 交易所是黑客攻击的目标
- 您的个人数据可能会被暴露
- 您并不真正拥有您的加密货币
如何在 Trezor 上使用VITA-FAST
请连接您的 Trezor 设备
打开第三方钱包应用
管理您的资产
充分利用您的 VITA-FAST
Trezor 助您安心管理 VITA-FAST
受安全芯片保护对抗在线与离线威胁的可靠防线
您的代币,您做主通过设备确认,全面掌控每笔交易
安全始于开源透明钱包设计让您的 Trezor 更优更安全
清晰简单的钱包备份采用新备份标准恢复您的数字资产访问权限
从第一天起就信心十足包装与设备防拆封条共同保障 Trezor 设备完整性
What is the project about?
VitaDAO, a decentralized autonomous organization, introduces VITA-FAST, an innovative funding model for longevity research. Leveraging the Ethereum blockchain, VITA-FAST are ERC-20 tokens, signifying fractional ownership of the Intellectual Property Non-Fungible Token (IP-NFT) from longevity research conducted at the Korolchuk Lab, Newcastle University. VITA-FAST token holders gain governance rights over the IP, democratizing the decision-making processes in scientific research.
- What is the project about?
The project is focused on discovering and developing therapeutic compounds that can reactivate autophagy in Npc1 -/- cells. This involves screening bioactive and commercial small molecules in cell survival assays to identify potential autophagy activators that are not cytotoxic. The project uses advanced techniques like luciferase-p6 clearance and Halo-GFP-LC3 orthogonal assays for this purpose.
- What makes your project unique?
The project's uniqueness lies in its approach to identifying novel compounds that can induce autophagy in NPC1 -/- cells, a crucial process for treating Niemann-Pick Type C disease. Unlike existing treatments, this project employs high-throughput screening methods and innovative assays to discover compounds with high chemical variability and no similarity to existing autophagy inducers, opening up possibilities for new iIP.
- History of your project.
The project, led by Dr. Korolchuk and his team at Newcastle University, has progressed from generating data on thousands of compounds using advanced screening assays to identifying lead compounds with potential autophagic properties. It has evolved to include the synthesis of derivatives of these compounds and is now moving towards drug translation processes, including pharmacokinetics and scalability studies.
- What’s next for your project?
The next steps involve screening third-generation compounds, conducting in vitro and in vivo models using patient